摘要
目的探讨术前三种血清肿瘤标志物(CA19-9、CA125及CEA)水平与胆囊癌患者手术预后的相关性。方法选择我院2005年1月至2013年12月接受胆囊癌根治术患者42例,所有患者术前均未经过放疗及化疗,术前检测其血清中CA19-9、CA125及CEA水平,术后对患者进行随访,分析这三肿瘤标志物血清水平与胆囊癌患者术后总体生存时间的相关性。结果与0~II期比较,III期胆囊癌患者的术前血清CEA、CA125及CA19-9平均水平均升高近2倍,但差异尚未达到统计学意义(P>0.05)。术前血清CEA、CA125及CA19-9水平在有无合并胆囊结石以及病理分化程度中比较,差异均无统计学意义(P>0.05)。术前血清CA125高水平中位生存时间明显短于低水平组(P=0.002);术前血清CA19-9高水平中位生存时间短于低水平组(P=0.031);然而,术前血清CEA水平与总体生存时间不相关(P=0.175)。联合监测结果显示,高水平组(CA125或CA19-9升高)的中位生存时间明显低于低水平组(CA125及CA19-9均降低)(P=0.002)。结论胆囊癌患者术前血清CA19-9及CA125水平有望成为判断手术预后的重要指标。
Objective To evaluate the prognostic values of preoperative serum levels of CA19-9, CA125 and CEA in patients with gallbladder cancer（GBC）. Methods A total of 42 GBC patients in our hospital from January 2005 to December 2013 were enrolled, no patient was treated with radiotherapy and chemotherapy before surgery, the serum levels of CA19-9, CA125 and CEA were detected in each patient. The patients were followed up, and the relationship between these three tumor biomarkers and the overall survival（OS） time were analyzed. Results Compared with stage 0-II, the levels of serum CEA, CA125 and CA19-9 in patients with stage III gallbladder carcinoma were nearly 2-fold higher, but the differ-ences were not statistically significant（P〈0.05）. There were no significant differences in the levels of serum CEA, CA125 and CA19-9 with different choledocholithiasis and pathological differentiation（P〈0.05）. The high level of preoperative serum CA125 had shorter median survival time than that of the low level group（P=0.002）; the high level of preoperative serum CA19-9 had shorter median survival time than that of the low level group（P=0.031）; but there was no significant difference in the preoperative serum CEA levels and overall survival time（P=0.175）. The joint detection results show that the median survival time of the high group（CA125 or CA19-9 increased） was shorter than that of the low group（CA125 or CA19-9 decreased）（P=0.002）. Conclusion Preoperative serum levels of CA125 and CA19-9 may potentially serve as the prognostic biomarker for GBC patients.
出处
《临床医学研究与实践》
2017年第31期7-8,11,共3页
Clinical Research and Practice
